Search research articles
Contact Us
Filters
Showing results (351-360 of 369) with videos related to
Page
of 37
Sort By:
JCO Global Oncology
|
June 29, 2021
Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
Verna D Vanderpuye, Jean Rene V Clemenceau, Sarah Temin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Linda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Page
of 37
Search research articles
Search
Showing results (351-360 of 369) with videos related to
Sort By:
Page
of 37
JCO Global Oncology
|
June 29, 2021
Assessment of Adult Women With Ovarian Masses and Treatment of Epithelial Ovarian Cancer: ASCO Resource-Stratified Guideline
Verna D Vanderpuye, Jean Rene V Clemenceau, Sarah Temin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 26, 2021
A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response
Linda R Duska, Virginia L Filiaci, Joan L Walker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2025
Comparing Durvalumab, Olaparib, and Cediranib Monotherapy, Combination Therapy, or Chemotherapy in Patients with Platinum-Resistant Ovarian Cancer with Prior Bevacizumab: The Phase II NRG-GY023 Trial
Jung-Min Lee, Austin Miller, Peter G Rose, et al.
Nature Communications
|
September 23, 2021
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A Konstantinopoulos, Alexandre André B A da Costa, Doga Gulhan, et al.
JCO Precision Oncology
|
April 18, 2024
Randomized Phase II Study of Gemcitabine With or Without ATR Inhibitor Berzosertib in Platinum-Resistant Ovarian Cancer: Final Overall Survival and Biomarker Analyses
Panagiotis A Konstantinopoulos, Su-Chun Cheng, Elizabeth K Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 15, 2022
Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
Joyce F Liu, Mark F Brady, Ursula A Matulonis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
February 23, 2017
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
Stephanie Lheureux, Zhongwu Lai, Brian A Dougherty, et al.
Gynecologic Oncology
|
May 17, 2024
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib
Joyce F Liu, Niya Xiong, Robert M Wenham, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 3, 2024
Cediranib and Olaparib Combination Compared With Cediranib or Olaparib Alone, or Chemotherapy in Platinum-Resistant or Primary Platinum-Refractory Ovarian Cancer: NRG-GY005
Jung-Min Lee, Mark F Brady, Austin Miller, et al.
Cancer Chemotherapy and Pharmacology
|
December 14, 2024
Dose finding, bioavailability, and PK-PD of oral triapine with concurrent chemoradiation for locally advanced cervical cancer and vaginal cancer (ETCTN 9892)
Sarah E Taylor, Sarah Behr, Kristine L Cooper, et al.
Page
of 37